0% (±8.0), 34.9% (± 6.3) and 19.9% (± 4.7), respectively,

and the mean percentage volume of bladder receiving 50 Gy and 70 Gy equal to 32.7% (±11.9) and 19.2% (± 8.2), respectively. In particular the maximum and mean dose to the rectum were 87.5 Gy (±1.2) and 42.5 Gy (±4.8), respectively; while the dose received by more than 1 and 5 cc of the rectum were 85.1 Gy (±1.3) PD0332991 mouse and 79.1 Gy (±4.3), respectively. Toxicity The IPSS questionnaire at baseline resulted in 36/39 (92%) of asymptomatic or low symptomatic patients (IPSS score ≤ 7), 3/39 (8%) moderate symptomatic (IPSS score 8–19), no patient was severely symptomatic (IPSS score 20–35). In our cohort, the acute side effects of radiotherapy were moderate and transient. No patient www.selleckchem.com/products/tariquidar.html experienced G3 or G4 acute gastrointestinal (GI) or genitourinary (GU) toxicity. G2 acute GI and GU toxicity were observed

in 17 (44%) and 20 (51%) patients, respectively (Figure 1). Fourteen patients (36%) did not experience acute GI and 4 patients (10%) did not experience acute GU toxicity. G2 late GI bleeding occurred in 7 of 39 patients (18%). Both G3 and G4 late GI toxicity were seen only in one patient (2.5%); in the first case G3 late GI toxicity was characterized by persistent bleeding treated with 4 sessions of laser coagulation, in Liproxstatin 1 the second case the G4 late GI toxicity was a fistula which required packing a temporary colostomy. Two patients (5%) experienced G2 late GU toxicity, while G3 late GU toxicity characterized by urethral

stricture occurred in 3 patients (8%), two of whom had undergone an endoscopic transurethral resection of prostate (TURP) before radiotherapy; Molecular motor no patient experienced G4 late GU toxicity (Figure 1). The actuarial analysis of ≥ G2 late GI and GU complications is reported in Figure 2. The 5-year actuarial incidence of ≥ G2 late GI and GU complications was 21.0% (std error 6.6%) and 12.8% (std error 5.4%), respectively. In Figure 3 mean dose volume histograms of the volume of rectum enclosed in the PTV are shown: a statistically significant difference was found between patients who did and did not experience late ≥2 GI toxicity (p < 0.0001 Mann–Whitney test). Figure 1 Incidence (% of patients) of acute and late gastrointestinal (GI) and genitourinary (GU) toxicity. Figure 2 Actuarial incidence of ≥ G2 late GI and GU toxicity. Figure 3 Mean dose volume histograms of the volume of rectum enclosed in the PTV for patients who did and did not experience late GI toxicity. Biochemical control rates and biopsies The 5-year actuarial FFBF after ultra-high IMRT dose of 86 Gy at 2 Gy/fraction was 87% (standard error 6%), without the use of ADT, as shown in Figure 4.